- Conditions
- Diabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME)
- Interventions
- ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3, Topical Steroid, ABBV-RGX-314 Dose 4, Aflibercept
- Genetic · Drug · Biological
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 25 Years to 89 Years
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 21 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Diabetic Macular Edema
- Interventions
- RGX-314 Dose 1, RGX-314 Dose 2, Aflibercept (2.0 mg)
- Genetic · Biological
- Lead sponsor
- Sierra Eye Associates
- Other
- Eligibility
- 25 Years to 89 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Reno, Nevada
- Conditions
- Diabetic Macular Edema
- Interventions
- intravitreous aflibercept, Bevacizumab + Deferred Aflibercept Group
- Drug
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 54
- States / cities
- Campbell, California • Glendale, California • Loma Linda, California + 46 more
- Conditions
- Diabetic Retinopathy
- Interventions
- Surabgene Lomparvovec, Sham, Topical Steroid, Artificial Tears
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 576 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2036
- U.S. locations
- 3
- States / cities
- Mountain View, California • Oak Forest, Illinois • Austin, Texas
- Conditions
- Center-involved Diabetic Macular Edema (CI-DME)
- Interventions
- Diabetes Visual Function Study (DiVFuSS) softgels, canola oil placebo softgels, 2 per day
- Dietary Supplement · Other
- Lead sponsor
- ZeaVision, LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 2
- States / cities
- Olympia, Washington • Tacoma, Washington
- Conditions
- Diabetic Macular Edema
- Interventions
- Prompt Laser, Prompt aflibercept, Deferred laser, Deferred aflibercept
- Procedure · Drug
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 702 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 100
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 84 more